These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33653635)

  • 21. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy.
    Aziz A; Gierth M; Fritsche HM; May M; Otto W; Denzinger S; Wieland WF; Merseburger A; Riedmiller H; Kocot A; Burger M
    Urol Int; 2013; 91(1):97-102. PubMed ID: 23751372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is high accuracy of Vesical Imaging-Reporting and Data System (VI-RADS) sufficient for its implementation in the urological practice?
    Rysankova K; Hanzlikova P; Zidlik V; Vrtkova A; Slisarenko M; Skarda J; Grepl M; Krhut J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar; 167(1):85-90. PubMed ID: 36628563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer.
    May M; Burger M; Brookman-May S; Stief CG; Fritsche HM; Roigas J; Zacharias M; Bader M; Mandel P; Gilfrich C; Seitz M; Tilki D
    Clin Genitourin Cancer; 2014 Aug; 12(4):278-86. PubMed ID: 24331576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implications of the COVID19 pandemic on the need and timing of second transurethral bladder tumour resection in high-grade non-muscle invasive bladder cancer.
    Vanneste M; van der Heij B; Christiaansen CE; Berendsen CL; Driessen EJM; Bruins HM
    World J Urol; 2023 Aug; 41(8):2173-2178. PubMed ID: 37328699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer.
    Mariappan P; Rai B; El-Mokadem I; Anderson CH; Lee H; Stewart S; Donat R
    Urology; 2015 Aug; 86(2):327-31. PubMed ID: 26142924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood-based protein biomarkers in bladder urothelial tumors.
    López-Cortés R; Gómez BB; Vázquez-Estévez S; Pérez-Fentes D; Núñez C
    J Proteomics; 2021 Sep; 247():104329. PubMed ID: 34298186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vesical Imaging-Reporting and Data System for Multiparametric MRI to Predict the Presence of Muscle Invasion for Bladder Cancer.
    Hong SB; Lee NK; Kim S; Son IW; Ha HK; Ku JY; Kim KH; Park WY
    J Magn Reson Imaging; 2020 Oct; 52(4):1249-1256. PubMed ID: 32220105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bladder cancer local staging: multiparametric MRI performance following transurethral resection.
    van der Pol CB; Shinagare AB; Tirumani SH; Preston MA; Vangel MG; Silverman SG
    Abdom Radiol (NY); 2018 Sep; 43(9):2412-2423. PubMed ID: 29313114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VI-RADS: Multiinstitutional Multireader Diagnostic Accuracy and Interobserver Agreement Study.
    Ueno Y; Tamada T; Takeuchi M; Sofue K; Takahashi S; Kamishima Y; Urase Y; Kido A; Hinata N; Harada K; Fujisawa M; Miyaji Y; Murakami T
    AJR Am J Roentgenol; 2021 May; 216(5):1257-1266. PubMed ID: 32755215
    [No Abstract]   [Full Text] [Related]  

  • 32. Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience.
    Rayn KN; Hale GR; Bloom JB; Gold SA; Carvalho FLF; Mehralivand S; Czarniecki M; Wood BJ; Merino MJ; Choyke P; Türkbey B; Pinto PA; Agarwal PK
    Diagn Interv Radiol; 2018 Sep; 24(5):316-320. PubMed ID: 30211685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical Imaging-Reporting and Data System): A systematic review.
    Carando R; Afferi L; Marra G; Krajewski W; Pagliarulo V; Abufaraj M; Xylinas E; Cathelineau X; Sanchez-Salas R; Moschini M
    Arab J Urol; 2020 Mar; 18(2):67-71. PubMed ID: 33029409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of local recurrences in the irradiated bladder: a systematic review.
    Sapre N; Anderson P; Foroudi F
    BJU Int; 2012 Dec; 110 Suppl 4():51-7. PubMed ID: 23194126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer.
    Onishi T; Sekito S; Shibahara T; Yabana T
    Urol Oncol; 2021 Feb; 39(2):132.e1-132.e6. PubMed ID: 32792215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer.
    Lai LY; Tafuri SM; Ginier EC; Herrel LA; Dahm P; Maisch P; Lane GI
    Cochrane Database Syst Rev; 2022 Apr; 4(4):CD014887. PubMed ID: 35393644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients.
    Rehme C; Fritsch B; Thomas L; Istin S; Burchert C; Hummel B; Baleanu-Curaj B; Reis H; Szarvas T; Ruebben H; Hadaschik B; Niedworok C
    Int Urol Nephrol; 2022 Jan; 54(1):71-79. PubMed ID: 34817753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
    Lindgren MS; Bue P; Azawi N; Blichert-Refsgaard L; Sundelin MO; Dyrskjøt L; Jensen JB
    Eur Urol; 2020 Dec; 78(6):856-862. PubMed ID: 32736928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.